8 March 2021: OIA response | Special Authority approvals for emtricitabine with tenofovir disoproxil

8 March 2021

Dear [name and contact details withheld]

REQUEST FOR INFORMATION

Further to our response to your request on 15 February 2021, please find in the table below the total number of Special Authority applications approved for emtricitabine with tenofovir disoproxil for the purpose of pre-exposure prophylaxis (PrEP) only.

Special Authority approvals for emtricitabine with tenofovir disoproxil

 

Auckland

Counties Manukau

Waitemata

 

Initial

Renewal

Initial

Renewal

Initial

Renewal

January 2019

46

117

2

16

16

32

February 2019

41

115

13

17

18

43

March 2019

68

150

9

14

18

58

April 2019

53

162

9

16

11

45

May 2019

47

164

13

21

23

39

June 2019

49

139

10

22

15

52

July 2019

57

191

5

16

19

64

August 2019

37

160

11

20

11

40

September 2019

32

144

8

28

24

59

October 2019

37

176

10

24

16

55

November 2019

48

179

11

27

10

62

December 2019

32

172

5

25

12

61

January 2020

31

166

6

30

6

55

February 2020

31

199

11

34

15

66

March 2020

25

193

5

18

9

61

April 2020

6

45

1

4

3

6

May 2020

22

165

 

25

7

53

June 2020

34

219

6

40

24

86

July 2020

40

154

7

25

13

50

August 2020

31

154

5

22

12

47

September 2020

28

222

6

39

8

69

October 2020

33

190

14

26

12

59

November 2020

38

208

2

38

18

72

December 2020

26

248

7

26

5

92

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.

Yours sincerely

Rachel Read
Manager, Policy and Government Services